Clincosm LogoSign in Get a demo

kras activating mutation

Showing 1 - 6 of 6
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Non Small Cell Lung Cancer, KRAS Activating Mutation Trial in United States (VS-6766 and sotorasib)

Recruiting
  • Non Small Cell Lung Cancer
  • KRAS Activating Mutation
  • avutometinib (VS-6766) and sotorasib
  • Washington, District of Columbia
  • +6 more
Jan 31, 2023

KRAS Activating Mutation, Metastatic Cancer, Pancreas Cancer Trial in Saint Louis (avutometinib (VS-6766) and defactinib in

Recruiting
  • KRAS Activating Mutation
  • +4 more
  • avutometinib (VS-6766) and defactinib in combination with gemcitabine and nab-paclitaxel
  • Saint Louis, Missouri
    Washington University School of Medicine
Jan 3, 2023

Non Small Cell Lung Cancer, KRAS Activating Mutation Trial in Worldwide (VS-6766, VS-6766 and Defactinib)

Recruiting
  • Non Small Cell Lung Cancer
  • KRAS Activating Mutation
  • avutometinib (VS-6766)
  • avutometinib (VS-6766) and Defactinib
  • Duarte, California
  • +44 more
Dec 22, 2022

Non Small Cell Lung Cancer, KRAS Activating Mutation, Advanced Cancer Trial in United States (VS-6766 and adagrasib)

Recruiting
  • Non Small Cell Lung Cancer
  • +5 more
  • avutometinib (VS-6766) and adagrasib
  • San Francisco, California
  • +4 more
Dec 21, 2022

Pancreatic Cancer, Small Bowel Cancer, Colorectal Cancer Trial in United States (Ulixertinib (BVD-523))

Available
  • Pancreatic Cancer
  • +20 more
  • Ulixertinib (BVD-523)
  • Birmingham, Alabama
  • +25 more
Nov 4, 2022

Lung Cancer, NSCLC, PD-L1 Gene Mutation Trial in Detroit (Durvalumab, Carboplatin, Pemetrexed)

Withdrawn
  • Lung Cancer
  • +3 more
  • Detroit, Michigan
    Henry Ford Health System
Feb 15, 2022